ravidasvir ravidasvir ravidasvir (ppi-668) is an investigational ns5a inhibitor (by pharco pharmaceuticals) in clinical trials for chronic hepatitis c genotype 4. ravidasvirclinical dataother namesppi-668atc codenoneidentifiers iupac name (2s)-2--1-amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1h-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one cas number1242087-93-9pubchem cid52918888chemspider31141686uniial3g001bi8chemblchembl3121849chemical and physical dataformulac42h50n8o6molar mass762.912 g·mol−13d model (jsmol)interactive image smiles cc(c)(c(=o)n1ccc1c2=nc3=c(n2)c=c(c=c3)c4=cc5=c(c=c4)c=c(c=c5)c6=cn=c(n6)7cccn7c(=o)(c(c)c)nc(=o)oc)nc(=o)oc inchi inchi=1s/c42h50n8o6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36h,7-10,17-18h2,1-6h3,(h,43,46)(h,44,45)(h,47,53)(h,48,54)/t33-,34-,35-,36-/m0/s1key:lchmhypwgwyxel-zyadhfcisa-n preliminary clinical trial results were announced in nov 2015. in april 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis c in a clinical trial conducted in malaysia and thailand, and 100% in another conducted in egypt. it has been granted conditional registration by the national pharmaceutical regulatory agency (npra) of malaysia.